GeneReach Biotechnology (ROCO:4171) Cyclically Adjusted Book per Share: NT$13.41 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4171 GeneReach Biotechnology Corp ROCO:4171
60 GF Score
Price NT$18.45
GF Value NT$23.98
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is GeneReach Biotechnology Cyclically Adjusted Book per Share?

GeneReach Biotechnology ROCO:4171 -5.87% 60 Cyclically Adjusted Book per Share is NT$13.41 as of Dec. 2025. GuruFocus rates ROCO:4171 with a GF Score™ of 60/100 and a GF Value™ of NT$23.98 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

GeneReach Biotechnology's adjusted book value per share for the three months ended in Dec. 2025 was NT$10.239. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is NT$13.41 for the trailing ten years ended in Dec. 2025.

During the past 12 months, GeneReach Biotechnology's average Cyclically Adjusted Book Growth Rate was 3.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-22), GeneReach Biotechnology's current stock price is NT$18.45. GeneReach Biotechnology's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2025 was NT$13.41. GeneReach Biotechnology's Cyclically Adjusted PB Ratio of today is 1.38.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of GeneReach Biotechnology was 6.34. The lowest was 1.26. And the median was 2.57.


GeneReach Biotechnology  (ROCO:4171) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

GeneReach Biotechnology's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=18.45/13.41
=1.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of GeneReach Biotechnology was 6.34. The lowest was 1.26. And the median was 2.57.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


GeneReach Biotechnology Cyclically Adjusted Book per Share Related Terms


GeneReach Biotechnology Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for GeneReach Biotechnology's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GeneReach Biotechnology Cyclically Adjusted Book per Share Chart

GeneReach Biotechnology Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 11.04 12.08 12.94

GeneReach Biotechnology Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.94 13.18 13.32 13.42 13.41

ROCO:4171 vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, GeneReach Biotechnology's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GeneReach Biotechnology Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GeneReach Biotechnology's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where GeneReach Biotechnology's Cyclically Adjusted PB Ratio falls into.


ROCO:4171
60GF Score
GeneReach Biotechnology Corp ROCO:4171
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GeneReach Biotechnology Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GeneReach Biotechnology's adjusted Book Value per Share data for the three months ended in Dec. 2025 was:

Adj_Book= Book Value per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=10.239/324.0540*324.0540
=10.239

Current CPI (Dec. 2025) = 324.0540.

GeneReach Biotechnology Quarterly Data

Book Value per Share CPI Adj_Book
201603 6.815 238.132 9.274
201606 6.772 241.018 9.105
201609 6.716 241.428 9.014
201612 6.290 241.432 8.443
201703 5.937 243.801 7.891
201706 6.002 244.955 7.940
201709 5.771 246.819 7.577
201712 5.156 246.524 6.778
201803 5.310 249.554 6.895
201806 5.657 251.989 7.275
201809 5.718 252.439 7.340
201812 5.893 251.233 7.601
201903 7.241 254.202 9.231
201906 8.877 256.143 11.231
201909 9.394 256.759 11.856
201912 9.669 256.974 12.193
202003 9.886 258.115 12.412
202006 11.340 257.797 14.255
202009 12.551 260.280 15.626
202012 14.150 260.474 17.604
202103 15.761 264.877 19.282
202106 17.653 271.696 21.055
202109 17.127 274.310 20.233
202112 18.271 278.802 21.237
202203 20.059 287.504 22.609
202206 22.447 296.311 24.549
202209 19.489 296.808 21.278
202212 18.582 296.797 20.289
202303 17.933 301.836 19.253
202306 15.913 305.109 16.901
202309 15.522 307.789 16.342
202312 14.481 306.746 15.298
202403 14.158 312.332 14.689
202406 13.540 314.175 13.966
202409 13.073 315.301 13.436
202412 12.478 315.605 12.812
202503 12.241 319.799 12.404
202506 10.839 322.561 10.889
202509 10.082 324.800 10.059
202512 10.239 324.054 10.239

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of NT$13.41 mean?
GeneReach Biotechnology (ROCO:4171) has a Cyclically Adjusted Book per Share of NT$13.41 as of Dec. 2025. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on GeneReach Biotechnology and its competitors.
Is GeneReach Biotechnology's Cyclically Adjusted Book per Share too high?
GeneReach Biotechnology's current Cyclically Adjusted Book per Share is NT$13.41. Overall, GeneReach Biotechnology has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GeneReach Biotechnology's Cyclically Adjusted Book per Share compare to VRTX and REGN?
GeneReach Biotechnology's Cyclically Adjusted Book per Share of NT$13.41 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on GeneReach Biotechnology and its competitors. GeneReach Biotechnology's current Cyclically Adjusted Book per Share is NT$13.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneReach Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, GeneReach Biotechnology (ROCO:4171) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$23.98, compared to a current price of NT$18.45 — trading 23.1% below its estimated fair value. The current Cyclically Adjusted Book per Share is NT$13.41. GeneReach Biotechnology's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For GeneReach Biotechnology (ROCO:4171), the current Cyclically Adjusted Book per Share is NT$13.41 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GeneReach Biotechnology (ROCO:4171) Overvalued in 2026?

Based on GuruFocus' analysis, GeneReach Biotechnology stock appears to be undervalued. The current stock price of NT$18.45 is trading 23.1% below its estimated GF Value™ of NT$23.98. GuruFocus considers GeneReach Biotechnology to be Modestly Undervalued.

Key valuation signals for ROCO:4171:

  • Cyclically Adjusted Book per Share: NT$13.41
  • GF Value™: NT$23.98 vs. price of NT$18.45 (23.1% below fair value)
  • GF Score™: 60/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4171 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GeneReach Biotechnology Business Description

Address No.19, Keyuan 2nd Road, Taichung, TWN, 407
GeneReach Biotechnology Corp is a biotechnology company. The company develops, manufactures and markets products for applied nucleic acid detection technology. Its products are utilised for aquaculture, agriculture, food, companion animal, livestock and human health industries.
60GF Score

Get the complete analysis for ROCO:4171

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$18.45
Price
NT$23.98
GF Value